Condensed Consolidated Balance Sheets (USD $) In Thousands	Sep. 30, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 8,539	$ 2,105
Available-for-sale securities	8,003	13,076
Accounts receivable	177	2,328
Receivable from Angiotech	160	106
Prepaid expenses and other	636	329
Total current assets	17,515	17,944
Equipment, net	1,318	955
Deposits and other	28	207
Total assets	18,861	19,106
Current liabilities:
Accounts payable	2,087	1,498
Accrued compensation and related benefits	466	580
Accrued clinical trial costs	865	207
Accrued expenses and other	798	1,012
Deferred revenue	2,966	5,541
Total current liabilities	7,182	8,838
Warrant liability	1,100	0
Deferred revenue	0	1,263
Stockholders' equity:
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at September 30, 2011 and December 31, 2010
Common stock, $0.001 par value; 100,000,000 shares authorized, and 23,503,926 and 18,930,678 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively	23	19
Additional paid-in capital	225,228	214,174
Accumulated other comprehensive income	36	26
Accumulated deficit	(214,708)	(205,214)
Total stockholders' equity	10,579	9,005
Total liabilities and stockholders' equity	$ 18,861	$ 19,106